Historical Valuation
Humacyte Inc (HUMA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 9.86 is considered Undervalued compared with the five-year average of -5.87. The fair price of Humacyte Inc (HUMA) is between 2.39 to 9.51 according to relative valuation methord. Compared to the current price of 1.19 USD , Humacyte Inc is Undervalued By 50.4%.
Relative Value
Fair Zone
2.39-9.51
Current Price：1.19
50.4%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Humacyte Inc (HUMA) has a current Price-to-Book (P/B) ratio of -32.60. Compared to its 3-year average P/B ratio of 3.32 , the current P/B ratio is approximately -1081.92% higher. Relative to its 5-year average P/B ratio of 3.38, the current P/B ratio is about -1063.50% higher. Humacyte Inc (HUMA) has a Forward Free Cash Flow (FCF) yield of approximately -56.55%. Compared to its 3-year average FCF yield of -24.29%, the current FCF yield is approximately 132.75% lower. Relative to its 5-year average FCF yield of -21.70% , the current FCF yield is about 160.63% lower.
P/B
Median3y
3.32
Median5y
3.38
FCF Yield
Median3y
-24.29
Median5y
-21.70
Competitors Valuation Multiple
AI Analysis for HUMA
The average P/S ratio for HUMA competitors is 78.06, providing a benchmark for relative valuation. Humacyte Inc Corp (HUMA.O) exhibits a P/S ratio of 9.86, which is -87.37% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for HUMA
1Y
3Y
5Y
Market capitalization of HUMA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of HUMA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is HUMA currently overvalued or undervalued?
Humacyte Inc (HUMA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 9.86 is considered Undervalued compared with the five-year average of -5.87. The fair price of Humacyte Inc (HUMA) is between 2.39 to 9.51 according to relative valuation methord. Compared to the current price of 1.19 USD , Humacyte Inc is Undervalued By 50.40% .
What is Humacyte Inc (HUMA) fair value?
HUMA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Humacyte Inc (HUMA) is between 2.39 to 9.51 according to relative valuation methord.
How does HUMA's valuation metrics compare to the industry average?
The average P/S ratio for HUMA's competitors is 78.06, providing a benchmark for relative valuation. Humacyte Inc Corp (HUMA) exhibits a P/S ratio of 9.86, which is -87.37% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Humacyte Inc (HUMA) as of Jan 10 2026?
As of Jan 10 2026, Humacyte Inc (HUMA) has a P/B ratio of -32.60. This indicates that the market values HUMA at -32.60 times its book value.
What is the current FCF Yield for Humacyte Inc (HUMA) as of Jan 10 2026?
As of Jan 10 2026, Humacyte Inc (HUMA) has a FCF Yield of -56.55%. This means that for every dollar of Humacyte Inc’s market capitalization, the company generates -56.55 cents in free cash flow.
What is the current Forward P/E ratio for Humacyte Inc (HUMA) as of Jan 10 2026?
As of Jan 10 2026, Humacyte Inc (HUMA) has a Forward P/E ratio of -2.08. This means the market is willing to pay $-2.08 for every dollar of Humacyte Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Humacyte Inc (HUMA) as of Jan 10 2026?
As of Jan 10 2026, Humacyte Inc (HUMA) has a Forward P/S ratio of 9.86. This means the market is valuing HUMA at $9.86 for every dollar of expected revenue over the next 12 months.